PRVB stock forecast
Our latest prediction for Provention Bio, Inc.'s stock price was made on the Dec. 20, 2019 when the stock price was at 11.41$.
In the short term (2weeks), PRVB's stock price should underperform the market by -4.63%. During that period the price should oscillate between -10.27% and +11.84%.
In the medium term (3months), PRVB's stock price should underperform the market by -6.80%. During that period the price should oscillate between -41.02% and +31.63%.Get email alerts
About Provention Bio, Inc.
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn's disease; PRV-300 for ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of T1D onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.83$ per share.
The book value per share is 1.74$
Three months stock forecastDec. 20, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|